One Home Health, Llc | |
833 W Lincoln Hwy, Suite 300, Schererville, Indiana 46375 | |
(219) 472-9820 | |
Name | One Home Health, Llc |
---|---|
Location | 833 W Lincoln Hwy, Suite 300, Schererville, Indiana |
Certified By | Medicare |
Services Offered | Nursing Care Physical Therapy Occupational Therapy Speech Pathology Medical Social Services Home Health Aide |
Medicare ID | 157662 |
Ownership Type | Proprietary |
Service Area Zip Codes | 46303, 46304, 46307, 46310, 46311, 46312, 46319, 46320, 46321, 46322, 46323, 46324, 46327, 46341, 46342, 46347, 46349, 46350, 46356, 46360, 46361, 46368, 46373, 46375, 46383, 46385, 46390, 46391, 46392, 46394, 46402, 46403, 46404, 46405, 46406, 46407, 46408, 46409, 46410 |
NPI Number | 1790046795 |
Organization Name | PEAK HOME HEALTH LLC |
Address | 8684 Connecticut St, Suite A2, Merrillville, IN 46410 |
Phone Number | 219-472-9820 |
News Archive
Heptares Therapeutics, the clinical-stage GPCR structure-guided drug discovery and development company, is delighted to announce that the Malcolm Campbell Memorial Prize for 2015 has been awarded to Miles Congreve (Vice President of Chemistry), Fiona Marshall (Chief Scientific Officer and co-founder) and Malcolm Weir (Chief Executive Officer and co-founder) for the seminal contributions to GPCR drug discovery made by Heptares Therapeutics since the company was founded in 2007.
Actavis plc today announced that it has received approval from the U.S. Food and Drug Administration on its Abbreviated New Drug Application for Telmisartan Immediate-Release Tablets, 20 mg, 40 mg and 80 mg, a generic equivalent to Boehringer Ingelheim's Micardis. Actavis intends to launch the product immediately.
A daily supplementation combination that included folic acid and vitamin B6 and B12 had no significant effect on the overall risk of cancer, including breast cancer, among women at high risk of cardiovascular disease, according to a study in the November 5 issue of JAMA, the Journal of the American Medical Association.
Agendia, a world leader in molecular cancer diagnostics, today announced the inauguration of a new state-of-the-art clinical genomics laboratory in Irvine, CA. Previously, Agendia's offices and laboratory were located in Huntington Beach, CA. The new laboratory will further increase capacity to support Agendia's strong commercial expansion in the U.S. market, as well as the use of multiple Agendia tests in clinical research. MammaPrint, the company's lead product and the only FDA-cleared breast cancer recurrence test, is reimbursed by an increasing number of payers, covering some 100 million lives today.
› Verified 2 days ago
Quality Rating: |
News Archive
Heptares Therapeutics, the clinical-stage GPCR structure-guided drug discovery and development company, is delighted to announce that the Malcolm Campbell Memorial Prize for 2015 has been awarded to Miles Congreve (Vice President of Chemistry), Fiona Marshall (Chief Scientific Officer and co-founder) and Malcolm Weir (Chief Executive Officer and co-founder) for the seminal contributions to GPCR drug discovery made by Heptares Therapeutics since the company was founded in 2007.
Actavis plc today announced that it has received approval from the U.S. Food and Drug Administration on its Abbreviated New Drug Application for Telmisartan Immediate-Release Tablets, 20 mg, 40 mg and 80 mg, a generic equivalent to Boehringer Ingelheim's Micardis. Actavis intends to launch the product immediately.
A daily supplementation combination that included folic acid and vitamin B6 and B12 had no significant effect on the overall risk of cancer, including breast cancer, among women at high risk of cardiovascular disease, according to a study in the November 5 issue of JAMA, the Journal of the American Medical Association.
Agendia, a world leader in molecular cancer diagnostics, today announced the inauguration of a new state-of-the-art clinical genomics laboratory in Irvine, CA. Previously, Agendia's offices and laboratory were located in Huntington Beach, CA. The new laboratory will further increase capacity to support Agendia's strong commercial expansion in the U.S. market, as well as the use of multiple Agendia tests in clinical research. MammaPrint, the company's lead product and the only FDA-cleared breast cancer recurrence test, is reimbursed by an increasing number of payers, covering some 100 million lives today.
› Verified 2 days ago
Quality Measure | Provider | National Avg. |
---|---|---|
How often the home health team began their patients’ care in a timely manner | 99.5 | 95.7 |
How often the home health team taught patients (or their family caregivers) about their drugs | 100 | 98.6 |
How often the home health team checked patients’ risk of falling | 100 | 99.6 |
How often the home health team checked patients for depression | 99.8 | 97.4 |
How often the home health team made sure that their patients have received a flu shot for the current flu season. | 86.2 | 78.7 |
How often the home health team made sure that their patients have received a pneumococcal vaccine (pneumonia shot). | 87.4 | 82.2 |
With diabetes, how often the home health team got doctor’s orders, gave foot care, and taught patients about foot care | 100 | 96.4 |
News Archive
Heptares Therapeutics, the clinical-stage GPCR structure-guided drug discovery and development company, is delighted to announce that the Malcolm Campbell Memorial Prize for 2015 has been awarded to Miles Congreve (Vice President of Chemistry), Fiona Marshall (Chief Scientific Officer and co-founder) and Malcolm Weir (Chief Executive Officer and co-founder) for the seminal contributions to GPCR drug discovery made by Heptares Therapeutics since the company was founded in 2007.
Actavis plc today announced that it has received approval from the U.S. Food and Drug Administration on its Abbreviated New Drug Application for Telmisartan Immediate-Release Tablets, 20 mg, 40 mg and 80 mg, a generic equivalent to Boehringer Ingelheim's Micardis. Actavis intends to launch the product immediately.
A daily supplementation combination that included folic acid and vitamin B6 and B12 had no significant effect on the overall risk of cancer, including breast cancer, among women at high risk of cardiovascular disease, according to a study in the November 5 issue of JAMA, the Journal of the American Medical Association.
Agendia, a world leader in molecular cancer diagnostics, today announced the inauguration of a new state-of-the-art clinical genomics laboratory in Irvine, CA. Previously, Agendia's offices and laboratory were located in Huntington Beach, CA. The new laboratory will further increase capacity to support Agendia's strong commercial expansion in the U.S. market, as well as the use of multiple Agendia tests in clinical research. MammaPrint, the company's lead product and the only FDA-cleared breast cancer recurrence test, is reimbursed by an increasing number of payers, covering some 100 million lives today.
› Verified 2 days ago
Quality Measure | Provider | National Avg. |
---|---|---|
How often patients got better at walking or moving around | 80.5 | 79.6 |
How often patients got better at getting in and out of bed | 80.3 | 81.1 |
How often patients got better at bathing | 80.2 | 82.3 |
How often patients’ breathing improved | 91.9 | 82.8 |
How often patients’ wounds improved or healed after an operation | 98.6 | 92.3 |
How often patients got better at taking their drugs correctly by mouth | 79.3 | 75 |
How often home health patients had to be admitted to the hospital | 15.3 | 15.4 |
How often patients receiving home health care needed urgent, unplanned care in the ER without being admitted | 11.6 | 13 |
How often physician-recommended actions to address medication issues were completely timely | 100 | 94 |
News Archive
Heptares Therapeutics, the clinical-stage GPCR structure-guided drug discovery and development company, is delighted to announce that the Malcolm Campbell Memorial Prize for 2015 has been awarded to Miles Congreve (Vice President of Chemistry), Fiona Marshall (Chief Scientific Officer and co-founder) and Malcolm Weir (Chief Executive Officer and co-founder) for the seminal contributions to GPCR drug discovery made by Heptares Therapeutics since the company was founded in 2007.
Actavis plc today announced that it has received approval from the U.S. Food and Drug Administration on its Abbreviated New Drug Application for Telmisartan Immediate-Release Tablets, 20 mg, 40 mg and 80 mg, a generic equivalent to Boehringer Ingelheim's Micardis. Actavis intends to launch the product immediately.
A daily supplementation combination that included folic acid and vitamin B6 and B12 had no significant effect on the overall risk of cancer, including breast cancer, among women at high risk of cardiovascular disease, according to a study in the November 5 issue of JAMA, the Journal of the American Medical Association.
Agendia, a world leader in molecular cancer diagnostics, today announced the inauguration of a new state-of-the-art clinical genomics laboratory in Irvine, CA. Previously, Agendia's offices and laboratory were located in Huntington Beach, CA. The new laboratory will further increase capacity to support Agendia's strong commercial expansion in the U.S. market, as well as the use of multiple Agendia tests in clinical research. MammaPrint, the company's lead product and the only FDA-cleared breast cancer recurrence test, is reimbursed by an increasing number of payers, covering some 100 million lives today.
› Verified 2 days ago
Question Type: | Rating by Patients |
---|---|
Health team gave care in a professional way | |
Health team communicated well with them | |
Health team discussed medicines, pain, and home safety | |
How patients rated overall care from agency |
News Archive
Heptares Therapeutics, the clinical-stage GPCR structure-guided drug discovery and development company, is delighted to announce that the Malcolm Campbell Memorial Prize for 2015 has been awarded to Miles Congreve (Vice President of Chemistry), Fiona Marshall (Chief Scientific Officer and co-founder) and Malcolm Weir (Chief Executive Officer and co-founder) for the seminal contributions to GPCR drug discovery made by Heptares Therapeutics since the company was founded in 2007.
Actavis plc today announced that it has received approval from the U.S. Food and Drug Administration on its Abbreviated New Drug Application for Telmisartan Immediate-Release Tablets, 20 mg, 40 mg and 80 mg, a generic equivalent to Boehringer Ingelheim's Micardis. Actavis intends to launch the product immediately.
A daily supplementation combination that included folic acid and vitamin B6 and B12 had no significant effect on the overall risk of cancer, including breast cancer, among women at high risk of cardiovascular disease, according to a study in the November 5 issue of JAMA, the Journal of the American Medical Association.
Agendia, a world leader in molecular cancer diagnostics, today announced the inauguration of a new state-of-the-art clinical genomics laboratory in Irvine, CA. Previously, Agendia's offices and laboratory were located in Huntington Beach, CA. The new laboratory will further increase capacity to support Agendia's strong commercial expansion in the U.S. market, as well as the use of multiple Agendia tests in clinical research. MammaPrint, the company's lead product and the only FDA-cleared breast cancer recurrence test, is reimbursed by an increasing number of payers, covering some 100 million lives today.
› Verified 2 days ago
The patient survey data of One Home Health, Llc is compared against the national average with the color code indicators: Better than National Average Worse than National AverageExperience Measure | Provider | National Avg. |
---|---|---|
Percent of patients who reported that their home health team gave care in a professional way | 91 | 88 |
Percent of patients who reported that their home health team communicated well with them | 90 | 85 |
Percent of patients who reported that their home health team discussed medicines, pain, and home safety with them | 84 | 83 |
Percent of patients who gave their home health agency a rating of 9 or 10 on a scale from 0 (lowest) to 10 (highest) | 89 | 84 |
Percent of patients who reported YES, they would definitely recommend the home health agency to friends and family | 80 | 78 |
News Archive
Heptares Therapeutics, the clinical-stage GPCR structure-guided drug discovery and development company, is delighted to announce that the Malcolm Campbell Memorial Prize for 2015 has been awarded to Miles Congreve (Vice President of Chemistry), Fiona Marshall (Chief Scientific Officer and co-founder) and Malcolm Weir (Chief Executive Officer and co-founder) for the seminal contributions to GPCR drug discovery made by Heptares Therapeutics since the company was founded in 2007.
Actavis plc today announced that it has received approval from the U.S. Food and Drug Administration on its Abbreviated New Drug Application for Telmisartan Immediate-Release Tablets, 20 mg, 40 mg and 80 mg, a generic equivalent to Boehringer Ingelheim's Micardis. Actavis intends to launch the product immediately.
A daily supplementation combination that included folic acid and vitamin B6 and B12 had no significant effect on the overall risk of cancer, including breast cancer, among women at high risk of cardiovascular disease, according to a study in the November 5 issue of JAMA, the Journal of the American Medical Association.
Agendia, a world leader in molecular cancer diagnostics, today announced the inauguration of a new state-of-the-art clinical genomics laboratory in Irvine, CA. Previously, Agendia's offices and laboratory were located in Huntington Beach, CA. The new laboratory will further increase capacity to support Agendia's strong commercial expansion in the U.S. market, as well as the use of multiple Agendia tests in clinical research. MammaPrint, the company's lead product and the only FDA-cleared breast cancer recurrence test, is reimbursed by an increasing number of payers, covering some 100 million lives today.
› Verified 2 days ago
Encompass Health Home Health Location: 752 E Us Hwy 30, Schererville, Indiana 46375 Ratings: Phone: (219) 864-9988 | |
American Home Health Services Inc Location: 940 West Us Highway 30, Schererville, Indiana 46375 Ratings: Phone: (219) 322-6264 | |
Assured Home Healthcare Inc Location: 1947 Harder Ct Ste B, Schererville, Indiana 46375 Ratings: Phone: (219) 322-7664 | |
One Home Health, Llc Location: 833 W Lincoln Hwy, Suite 300, Schererville, Indiana 46375 Ratings: Phone: (219) 472-9820 |